GlobalData on MSN

ICR scientists develop algorithm that predicts bowel cancer risk in IBD patients

Scientists from the Institute of Cancer Research (ICR), London, UK, have developed an algorithm that can predict whether ...
Medscape

Subcutaneous Guselkumab Proves Efficacious for IBD in Two Studies: ASTRO and GRAVITI

BERLIN — Induction therapy with subcutaneous guselkumab demonstrated significant efficacy in patients with moderately to severely active ulcerative colitis (UC), according to results from the phase 3, ...
European Medical Journal

Shared T Cell Signatures Identified In IBD

Shared TCR signatures in IBD linked to HLA-DRB1 reveal common immune mechanisms across ulcerative colitis and Crohn’s disease ...
Nasdaq

Teva and Sanofi’s duvakitug phase 2b maintenance data demonstrated clinically meaningful durable efficacy in ulcerative colitis and Crohn’s disease

In the RELIEVE UCCD LTE phase 2b study, duvakitug showed robust, durable efficacy for an additional 44 weeks in UC and CD patients who had responded after 14 weeks of induction Duvakitug was well ...